ERTUGLIFLOZIN AND METFORMIN HYDROCHLORIDE

ERTUGLIFLOZIN AND METFORMIN HYDROCHLORIDE was reported 82 times

These side effects are most commonly reported by patients taking ERTUGLIFLOZIN AND METFORMIN HYDROCHLORIDE:

# Side effect Count
0 PRODUCT DOSE OMISSION ISSUE 11
1 NO ADVERSE EVENT 8
2 NAUSEA 7
3 DIABETIC KETOACIDOSIS 6
4 VOMITING 6
5 ASTHENIA 5
6 DIARRHOEA 4
7 INABILITY TO AFFORD MEDICATION 4
8 BLOOD GLUCOSE INCREASED 3
9 DECREASED APPETITE 3
10 DRUG INEFFECTIVE 3
11 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 3
12 INFLUENZA 3
13 PRODUCT DOSE OMISSION 3
14 PRODUCT USE ISSUE 3
15 ABDOMINAL DISTENSION 2
16 ADVERSE EVENT 2
17 ASPIRATION 2
18 BACK PAIN 2
19 BLOOD GLUCOSE FLUCTUATION 2
20 CONSTIPATION 2
21 EPIGASTRIC DISCOMFORT 2
22 FUNGAL INFECTION 2
23 GLYCOSYLATED HAEMOGLOBIN ABNORMAL 2
24 HEADACHE 2
25 HYPOTENSION 2
26 INTENTIONAL PRODUCT MISUSE 2
27 LACTIC ACIDOSIS 2
28 MALAISE 2
29 RASH 2
30 TOE AMPUTATION 2
31 URINARY TRACT INFECTION 2
32 VISUAL IMPAIRMENT 2
33 WEIGHT DECREASED 2
34 ABDOMINAL PAIN 1
35 ABDOMINAL PAIN UPPER 1
36 ACUTE KIDNEY INJURY 1
37 ACUTE MYOCARDIAL INFARCTION 1
38 AGITATION 1
39 ANAPHYLACTIC REACTION 1
40 APPLICATION SITE ERYTHEMA 1
41 APPLICATION SITE IRRITATION 1
42 APPLICATION SITE PAIN 1
43 APPLICATION SITE SCAB 1
44 ATRIAL FIBRILLATION 1
45 BENIGN PROSTATIC HYPERPLASIA 1
46 BLOOD COUNT ABNORMAL 1
47 BLOOD CREATININE INCREASED 1
48 BLOOD GLUCOSE ABNORMAL 1
49 CARDIAC DISORDER 1
50 CARDIAC FLUTTER 1
51 CONTUSION 1
52 CYSTITIS 1
53 CYSTITIS HAEMORRHAGIC 1
54 DEATH 1
55 DEEP VEIN THROMBOSIS 1
56 DEVICE DELIVERY SYSTEM ISSUE 1
57 DEVICE ISSUE 1
58 DEVICE LEAKAGE 1
59 DEVICE MECHANICAL ISSUE 1
60 DIZZINESS 1
61 DRUG HYPERSENSITIVITY 1
62 DRY MOUTH 1
63 DRY SKIN 1
64 DYSPHORIA 1
65 DYSPNOEA 1
66 DYSURIA 1
67 ECZEMA 1
68 ERECTILE DYSFUNCTION 1
69 EXPOSURE VIA SKIN CONTACT 1
70 FALL 1
71 FATIGUE 1
72 FLATULENCE 1
73 FLUID RETENTION 1
74 GASTRIC HYPOMOTILITY 1
75 GASTROINTESTINAL TRACT IRRITATION 1
76 GASTROOESOPHAGEAL REFLUX DISEASE 1
77 GLOMERULAR FILTRATION RATE DECREASED 1
78 HERNIA REPAIR 1
79 HOSPITALISATION 1
80 HYPERSENSITIVITY 1
81 HYPERTENSION 1
82 HYPERTHYROIDISM 1
83 HYPOAESTHESIA 1
84 HYPOPHAGIA 1
85 HYPOVOLAEMIA 1
86 IMPAIRED GASTRIC EMPTYING 1
87 INCORRECT DOSE ADMINISTERED 1
88 INCORRECT PRODUCT ADMINISTRATION DURATION 1
89 INJECTION SITE DISCOLOURATION 1
90 INJECTION SITE INDENTATION 1
91 INJECTION SITE INFLAMMATION 1
92 INJECTION SITE OEDEMA 1
93 INJECTION SITE PAIN 1
94 INJECTION SITE REACTION 1
95 INSOMNIA 1
96 INSURANCE ISSUE 1
97 IRRITABILITY 1
98 KETOACIDOSIS 1
99 KUSSMAUL RESPIRATION 1
100 LACRIMATION INCREASED 1
101 LOSS OF CONSCIOUSNESS 1
102 LOW DENSITY LIPOPROTEIN INCREASED 1
103 MALIGNANT NEOPLASM PROGRESSION 1
104 METASTASES TO LIVER 1
105 MOOD ALTERED 1
106 MUSCLE DISCOMFORT 1
107 MUSCLE FATIGUE 1
108 MYALGIA 1
109 MYOCARDIAL INFARCTION 1
110 NEUROENDOCRINE CARCINOMA 1
111 OFF LABEL USE 1
112 ORTHOSTATIC HYPOTENSION 1
113 PAIN 1
114 PERIORBITAL SWELLING 1
115 PERIPHERAL SWELLING 1
116 PHARYNGEAL INFLAMMATION 1
117 PLATELET COUNT DECREASED 1
118 PRODUCT QUALITY ISSUE 1
119 PRODUCT USE IN UNAPPROVED INDICATION 1
120 RELAPSING FEVER 1
121 RENAL IMPAIRMENT 1
122 RENAL PAIN 1
123 RESTLESSNESS 1
124 ROAD TRAFFIC ACCIDENT 1
125 SOMNOLENCE 1
126 SYNCOPE 1
127 TACHYCARDIA 1
128 THERAPY CESSATION 1
129 THROAT IRRITATION 1
130 TONGUE DISCOMFORT 1
131 TYPE 1 DIABETES MELLITUS 1
132 URINARY HESITATION 1
133 VAGINAL DISCHARGE 1
134 VAGINAL HAEMORRHAGE 1
135 VISION BLURRED 1
136 VULVOVAGINAL MYCOTIC INFECTION 1
137 VULVOVAGINITIS 1
138 WEIGHT ABNORMAL 1
139 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 1